FR21C1005I2 - Antigenes de streptococcus pyogenes et fragments d'adn correspondants - Google Patents

Antigenes de streptococcus pyogenes et fragments d'adn correspondants

Info

Publication number
FR21C1005I2
FR21C1005I2 FR21C1005C FR21C1005C FR21C1005I2 FR 21C1005 I2 FR21C1005 I2 FR 21C1005I2 FR 21C1005 C FR21C1005 C FR 21C1005C FR 21C1005 C FR21C1005 C FR 21C1005C FR 21C1005 I2 FR21C1005 I2 FR 21C1005I2
Authority
FR
France
Prior art keywords
streptococcus pyogenes
dna fragments
corresponding dna
antigens
pyogenes antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR21C1005C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ID Biomedical Corp of Quebec
Original Assignee
ID Biomedical Corp of Quebec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ID Biomedical Corp of Quebec filed Critical ID Biomedical Corp of Quebec
Publication of FR21C1005I1 publication Critical patent/FR21C1005I1/fr
Application granted granted Critical
Publication of FR21C1005I2 publication Critical patent/FR21C1005I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56944—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/315—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Streptococcus (G), e.g. Enterococci
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
FR21C1005C 2000-12-21 2021-02-04 Antigenes de streptococcus pyogenes et fragments d'adn correspondants Active FR21C1005I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25694000P 2000-12-21 2000-12-21
PCT/CA2001/001853 WO2002050107A2 (en) 2000-12-21 2001-12-21 Streptococcus pyogenes antigens and corresponding dna fragments

Publications (2)

Publication Number Publication Date
FR21C1005I1 FR21C1005I1 (enExample) 2021-03-26
FR21C1005I2 true FR21C1005I2 (fr) 2022-01-14

Family

ID=22974225

Family Applications (1)

Application Number Title Priority Date Filing Date
FR21C1005C Active FR21C1005I2 (fr) 2000-12-21 2021-02-04 Antigenes de streptococcus pyogenes et fragments d'adn correspondants

Country Status (12)

Country Link
US (5) US7595057B2 (enExample)
EP (1) EP1343895B1 (enExample)
JP (1) JP4080876B2 (enExample)
AT (1) ATE398677T1 (enExample)
AU (2) AU2002216863B8 (enExample)
BE (1) BE2021C506I2 (enExample)
BR (1) BR0116704A (enExample)
CA (2) CA2789252C (enExample)
DE (1) DE60134494D1 (enExample)
ES (1) ES2307564T3 (enExample)
FR (1) FR21C1005I2 (enExample)
WO (1) WO2002050107A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60134494D1 (de) * 2000-12-21 2008-07-31 Id Biomedical Corp Antigene aus streptococcus pyogenes und zugehörige dna-fragmente
GB0130228D0 (en) * 2001-12-18 2002-02-06 Hansa Medica Ab Protein
WO2005017093A2 (en) * 2003-08-15 2005-02-24 Id Biomedical Corporation Polypeptides of streptococcus pyogenes
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502306D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
WO2024206953A2 (en) * 2023-03-29 2024-10-03 Taktos Therapeutics Inc. Ides variant proteins and methods of using the same

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854416A (en) * 1991-11-14 1998-12-29 The United States Of America As Represented By The Department Of Health And Human Services Streptococcus pneumoniae 37-KDA surface adhesin a protein and nucleic acids coding therefor
US6287574B1 (en) 1995-03-17 2001-09-11 Biochem Pharma Inc. Proteinase K resistant surface protein of neisseria meningitidis
WO1999042588A2 (en) * 1998-02-20 1999-08-26 Biochem Pharma Inc. Group b streptococcus antigens
GB9807890D0 (en) * 1998-04-09 1998-06-10 Actinova Ltd Peptides
CA2337102A1 (en) 1998-07-27 2000-02-10 Richard William Falla Le Page Nucleic acids and proteins from group b streptococcus
EP2053126A1 (en) 1998-07-27 2009-04-29 Sanofi Pasteur Limited Streptococcus pneumoniae proteins and nucleic acid molecules
US7128918B1 (en) * 1998-12-23 2006-10-31 Id Biomedical Corporation Streptococcus antigens
GB9828880D0 (en) * 1998-12-31 1999-02-17 Actinova Ltd Protein
US7074415B2 (en) * 2000-06-20 2006-07-11 Id Biomedical Corporation Streptococcus antigens
AU7227001A (en) * 2000-07-06 2002-01-21 Shire Biochem Inc Streptococcus pyogenes antigens
AU2002210301A1 (en) * 2000-10-13 2002-04-22 Shire Biochem Inc. Bvh-a2 and bvh-a3 antigens of group b streptococcus
US7939087B2 (en) * 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
DE60134494D1 (de) * 2000-12-21 2008-07-31 Id Biomedical Corp Antigene aus streptococcus pyogenes und zugehörige dna-fragmente
BRPI0207447B1 (pt) * 2001-02-21 2015-09-22 Id Biomedical Corp polipeptídeo recombinante isolado, seu uso e processo de produção, vetor de expressão, célula hospedeira microbiana transgênica, composição farmacêutica, uso da dita composição, métodos de detecção e kit
US20040236072A1 (en) * 2001-04-13 2004-11-25 Olmsted Stephen Bruce Surface proteins of streptococcus pyogenes
EP1407023B1 (en) * 2001-07-06 2009-12-16 ID Biomedical Corporation Group b streptococcus antigens and corresponding dna fragments
GB0130228D0 (en) * 2001-12-18 2002-02-06 Hansa Medica Ab Protein
AU2002351623A1 (en) * 2001-12-20 2003-07-09 Shire Biochem Inc. Streptococcus antigens
AU2003246495A1 (en) * 2002-07-15 2004-02-02 Id Biomedical Corporation Polypeptide of streptococcus pyogenes
WO2005017093A2 (en) * 2003-08-15 2005-02-24 Id Biomedical Corporation Polypeptides of streptococcus pyogenes
US7838010B2 (en) * 2004-10-08 2010-11-23 Novartis Vaccines And Diagnostics S.R.L. Immunogenic and therapeutic compositions for Streptococcus pyogenes
ES2380950T3 (es) * 2005-06-09 2012-05-21 Hansa Medical Ab Uso de la proteinasa IdeS ( de S, pyogenes) para tratar enfermedades autoinmunitarias y rechazo de injerto
US8309096B2 (en) * 2007-01-15 2012-11-13 Glaxosmithkline Biologicals S.A. Fusion protein
WO2009033670A2 (en) * 2007-09-14 2009-03-19 Genovis Ab Method and kits for dissociating fcgamma-receptor-igg complexes and for igg purification and detection
GB201003920D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
GB201115841D0 (en) * 2011-09-13 2011-10-26 Genovis Ab Protein and method
GB201316744D0 (en) * 2013-09-20 2013-11-06 Genovis Ab Method
GB201416849D0 (en) * 2014-09-24 2014-11-05 Genovis Ab Method

Also Published As

Publication number Publication date
US7595057B2 (en) 2009-09-29
JP2004524014A (ja) 2004-08-12
EP1343895B1 (en) 2008-06-18
CA2789252A1 (en) 2002-06-27
US9340586B2 (en) 2016-05-17
WO2002050107A3 (en) 2003-04-10
EP1343895A2 (en) 2003-09-17
CA2432525C (en) 2012-11-27
US20130136760A1 (en) 2013-05-30
US8298551B2 (en) 2012-10-30
CA2789252C (en) 2016-11-15
ES2307564T9 (es) 2021-04-26
BR0116704A (pt) 2003-12-23
US20150017684A1 (en) 2015-01-15
DE60134494D1 (de) 2008-07-31
US20100119507A1 (en) 2010-05-13
US20160326221A1 (en) 2016-11-10
ES2307564T3 (es) 2008-12-01
ATE398677T1 (de) 2008-07-15
AU2002216863B2 (en) 2008-02-28
US20040097706A1 (en) 2004-05-20
BE2021C506I2 (enExample) 2021-05-31
AU2002216863B8 (en) 2008-03-20
JP4080876B2 (ja) 2008-04-23
US8821895B2 (en) 2014-09-02
WO2002050107A2 (en) 2002-06-27
FR21C1005I1 (enExample) 2021-03-26
CA2432525A1 (en) 2002-06-27
AU1686302A (en) 2002-07-01

Similar Documents

Publication Publication Date Title
FR21C1005I2 (fr) Antigenes de streptococcus pyogenes et fragments d'adn correspondants
NZ524888A (en) Nucleic acids and proteins from streptococcus groups A & B
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
YU9403A (sh) Anti-dualna antitela integrina, kompozicije, postupci i primene
AU2001295671A1 (en) Pharmaceutical composition for immunisation against aids
DE60136360D1 (de) Antigen aus streptococcus pyogenes
WO2004043407A3 (en) Methods and products for treating staphylococcal infections
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
NO20030407D0 (no) Silikatformidlet syntese av omorfe silikater og siloksaner og anvendelse avdette
WO2002060917A3 (en) Method to treat hemophilia
ATE321853T1 (de) Humanische pellino-polypeptide
DK2335720T3 (da) Autolog T-cellevacciner mod multiple sclerose
YU68602A (sh) Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje
DE60235223D1 (de) Streptococcus pyogenes polypeptide und entsprechende dna fragmente
DE60125528D1 (de) Isolierung und charakterisierung des csa-operons (etec-cs4 pili) und verfahren zu dessen anwendung
BR0111785A (pt) Composições e métodos para tratamento de candidìase
DK0792347T3 (da) Fremgangsmåder til fremstilling af forbedrede antigene Heliobacter sp. og vacciner omfattende samme
DE60234772D1 (de) Gruppe-b streptococcus antigene und entsprechende dna-fragmente
WO2001064840A8 (en) Novel bone marrow nucleic acids and polypeptides
WO2002088178A8 (en) Antigens of group b streptococcus and corresponding dna fragments
AU6709500A (en) Trehalose producing cells as vaccines
MY155265A (en) Anti-dual integrin antibodies, compositions, methods and uses